Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Department of Pharmacology, Clinical Pharmacology, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
J Musculoskelet Neuronal Interact. 2020 Sep 1;20(3):339-346.
To examine the effect of denosumab administration in the peripheral blood white cell population, to further elucidate a plausible pathophysiological link between denosumab and osteonecrosis of the jaw.
Thirty women with osteoporosis, after denosumab treatment were included. Peripheral blood samples were obtained prior to and 48-72 hours following denosumab administration. Flow cytometry gated at the monocyte population for CD14/CD23/CD123/CD16 stainings were performed.
We were able to record a number of changes in the monocyte populations between baseline and after denosumab administration. Most importantly, in the monocyte populations we were able to detect statistically significant increased populations of CD14+/CD23+ (p=0.044), CD14-/CD23+ (p=0.044), CD14+/CD123+ (p=0.011), CD14+/CD123- (p=0.011) and CD14-/CD16+ (p=0.028). In contrast, statistically significant decreased populations of CD14-/CD123+ (p=0.034), CD14+/CD16+ (p=0.037) and CD14+/CD16- (p=0.014) were detected.
Our results provide evidence supporting the hypothesis that denosumab administration modifies the monocyte mediated immune response in a manner similar to that of bisphosphonates. This may partly explain the trivial immunity changes recorded with denosumab.
研究地舒单抗给药对外周血白细胞群的影响,进一步阐明地舒单抗与颌骨骨坏死之间可能存在的病理生理学联系。
纳入 30 例接受地舒单抗治疗的骨质疏松症女性患者。在给予地舒单抗前和给药后 48-72 小时采集外周血样本。采用流式细胞术,以单核细胞群体为门控,进行 CD14/CD23/CD123/CD16 染色。
我们能够记录到基线和地舒单抗给药后单核细胞群之间的一些变化。最重要的是,在单核细胞群中,我们能够检测到 CD14+/CD23+(p=0.044)、CD14-/CD23+(p=0.044)、CD14+/CD123+(p=0.011)、CD14+/CD123-(p=0.011)和 CD14-/CD16+(p=0.028)的群体显著增加。相比之下,CD14-/CD123+(p=0.034)、CD14+/CD16+(p=0.037)和 CD14+/CD16-(p=0.014)的群体显著减少。
我们的结果提供了证据,支持地舒单抗给药以类似于双膦酸盐的方式改变单核细胞介导的免疫反应的假说。这可能部分解释了地舒单抗记录到的轻微免疫变化。